BidaskClub cut shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a hold rating to a sell rating in a research report released on Saturday.
AGIO has been the topic of several other research reports. Canaccord Genuity reaffirmed a buy rating and issued a $90.00 price target on shares of Agios Pharmaceuticals in a report on Wednesday, September 5th. Piper Jaffray Companies set a $125.00 price target on Agios Pharmaceuticals and gave the company a buy rating in a report on Thursday, August 2nd. SunTrust Banks reaffirmed a buy rating and issued a $123.00 price target on shares of Agios Pharmaceuticals in a report on Monday, July 23rd. Leerink Swann began coverage on Agios Pharmaceuticals in a report on Monday, September 24th. They issued a market perform rating and a $80.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a buy rating on shares of Agios Pharmaceuticals in a report on Thursday, August 2nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and ten have assigned a buy rating to the stock. Agios Pharmaceuticals currently has a consensus rating of Buy and a consensus price target of $96.27.
NASDAQ:AGIO opened at $68.10 on Friday. Agios Pharmaceuticals has a twelve month low of $51.62 and a twelve month high of $99.82. The stock has a market capitalization of $4.47 billion, a price-to-earnings ratio of -10.09 and a beta of 1.73.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, beating the consensus estimate of ($1.62) by $0.43. Agios Pharmaceuticals had a negative return on equity of 51.71% and a negative net margin of 462.08%. The firm had revenue of $40.40 million for the quarter, compared to analysts’ expectations of $12.47 million. During the same quarter last year, the firm posted ($1.78) EPS. The company’s revenue was up 257.5% compared to the same quarter last year. As a group, equities research analysts forecast that Agios Pharmaceuticals will post -6.11 earnings per share for the current year.
In other news, insider Steven L. Hoerter sold 2,050 shares of the stock in a transaction dated Wednesday, July 25th. The stock was sold at an average price of $84.58, for a total transaction of $173,389.00. Following the transaction, the insider now directly owns 2,050 shares in the company, valued at approximately $173,389. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Maraganore sold 13,555 shares of the stock in a transaction dated Tuesday, September 11th. The shares were sold at an average price of $72.75, for a total value of $986,126.25. Following the transaction, the director now owns 38,609 shares in the company, valued at $2,808,804.75. The disclosure for this sale can be found here. Insiders have sold a total of 25,355 shares of company stock worth $1,938,692 over the last quarter. Corporate insiders own 3.02% of the company’s stock.
Several institutional investors have recently made changes to their positions in AGIO. Wells Fargo & Company MN grew its position in Agios Pharmaceuticals by 2.4% during the 1st quarter. Wells Fargo & Company MN now owns 72,776 shares of the biopharmaceutical company’s stock worth $5,952,000 after acquiring an additional 1,711 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in Agios Pharmaceuticals by 24.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 151,812 shares of the biopharmaceutical company’s stock worth $12,416,000 after acquiring an additional 29,837 shares during the last quarter. Aperio Group LLC bought a new position in Agios Pharmaceuticals during the 1st quarter worth approximately $311,000. Northern Trust Corp grew its position in Agios Pharmaceuticals by 15.3% during the 1st quarter. Northern Trust Corp now owns 269,108 shares of the biopharmaceutical company’s stock worth $22,008,000 after acquiring an additional 35,708 shares during the last quarter. Finally, BlackRock Inc. grew its position in Agios Pharmaceuticals by 14.0% during the 1st quarter. BlackRock Inc. now owns 3,206,053 shares of the biopharmaceutical company’s stock worth $262,192,000 after acquiring an additional 393,336 shares during the last quarter. Hedge funds and other institutional investors own 93.63% of the company’s stock.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Read More: Call Option
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.